In short
This article discusses ongoing clinical trials investigating the use of Human IgG1K Monoclonal Antibody Against TIM-3, also known as INCAGN02390, in treating various types of cancer. The trials aim to evaluate the safety and effectiveness of this antibody, either alone or in combination with other therapies, for patients with advanced endometrial cancer and head and neck cancer. These studies represent important steps in developing new immunotherapy options for cancer patients.
At a glance
- Drug Name
- Human IgG1K Monoclonal Antibody Against TIM-3 (INCAGN02390)
- Cancer Types Studied
- Advanced/metastatic endometrial cancer, Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
- Administration Method
- Intravenous infusion
- Study Designs
- Phase 2 trials, Combination therapy with other immunotherapy drugs
- Primary Objectives
- Evaluate safety and efficacy, Measure tumor response rates, Assess progression-free survival
- Key Inclusion Criteria
- Adults with specific cancer types, Measurable disease, Adequate organ function
- Key Exclusion Criteria
- Active autoimmune diseases, Certain infections (HIV, hepatitis), Recent use of other immunotherapies
- Outcome Measures
- Objective response rate, Duration of response, Overall survival, Safety profile
What is INCAGN02390?
INCAGN02390 is a human IgG1k monoclonal antibody that targets a protein called TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3). It is being developed by Incyte Corporation as a potential new treatment for various types of cancer. This medication is classified as a biological or biotechnological product, which means it is derived from living organisms and designed to interact with specific targets in the body.
How does it work?
INCAGN02390 works by targeting and blocking TIM-3, a protein found on the surface of certain immune cells. TIM-3 is known to play a role in suppressing the immune system's ability to fight cancer. By blocking TIM-3, INCAGN02390 aims to enhance the immune system's response against cancer cells, potentially leading to better control of tumor growth and spread.
What conditions does it treat?
Based on the available clinical trial information, INCAGN02390 is being studied for the treatment of several types of cancer, including:
- Endometrial cancer: This is cancer that starts in the lining of the uterus (endometrium).
- Squamous Cell Carcinoma of the Head and Neck (SCCHN): This refers to cancers that develop in the mouth, nose, throat, or other areas of the head and neck.
It's important to note that INCAGN02390 is still in the experimental stage and is not yet approved for general use outside of clinical trials.
Clinical Trials
INCAGN02390 is currently being evaluated in several clinical trials:
- Endometrial Cancer Study: This trial is investigating INCAGN02390 in combination with other drugs for patients with advanced or metastatic endometrial cancer who have progressed after platinum-based chemotherapy.
- Head and Neck Cancer Study: This is a Phase 2 study examining INCAGN02390 in combination with other immunotherapy drugs for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients whose tumors are positive for a protein called PD-L1.
These trials aim to determine how effective INCAGN02390 is in treating these cancers, either alone or in combination with other drugs, and to assess its safety profile.
Administration
INCAGN02390 is administered as a solution for infusion, which means it is given directly into the bloodstream through a vein (intravenously). The dosage and frequency of administration may vary depending on the specific clinical trial and the patient's condition.
Potential Side Effects
As INCAGN02390 is still in clinical trials, the full range of potential side effects is not yet known. However, as with other immunotherapy drugs, it may cause side effects related to increased immune system activity. These could potentially include:
- Fatigue
- Skin reactions
- Gastrointestinal issues
- Immune-related adverse events
It's important to note that the clinical trials are closely monitoring for any adverse events to ensure patient safety.
Conclusion
INCAGN02390 represents a promising new approach in cancer immunotherapy. By targeting TIM-3, it aims to enhance the body's natural defenses against cancer. While still in the experimental stage, ongoing clinical trials are providing valuable information about its effectiveness and safety in treating endometrial cancer and head and neck cancer. As research progresses, we may learn more about its potential applications in other types of cancer as well.